Comparative analysis of the results of surgical treatment for patients with lung cancer and concomitant coronary heart disease after prophylactic myocardial revascularization and for patients with lung cancer without CAD

Introduction. Objective. The feasibility of prophylactic myocardial revascularization in planning non-cardiac surgical interventions remains as a subject of debate today.

Purpose of the study. To compare the immediate and long-term results of surgical treatment of patients with lung cancer with concomitant CAD, when prophylactic myocardial revascularization was performed, with operated patients with lung cancer without CAD.

Materials and methods. The study included 134 patients operated on for lung cancer, 126 (94,0 %) men and 8 (6,1 %) women, the mean age was 63,9 years (from 36 to 81). Of these, the main group: 63 (47 %) patients with concomitant CAD, when prophylactic myocardial revascularization was performed, and the control group: 71 (53 %) patients without concomitant CAD (or who does not need prophylactic revascularization).

Results: the incidence of postoperative complications in the main and control groups was 33,3 % (21/63) and 25,4 % (18/71) (p=0,453), and mortality was 1,6 % (1/63) and 4,2 % (3/71) (p=0,385), respectively. Perioperative myocardial infarction in the main group was registered in 3,2 % (2/63) with a fatal outcome in 1,6% (1/63), and in the control group it was 0 % (0/71) (p=0,137; p=0,291).

The overall 1-, 3-, and 5-year survival of radically operated patients in the main group was 81,7%; 67,6%; 50,0%, and in the control group – 86,8 %, 62,5 %, 53,8 % (p=0,750), respectively.

Conclusions. Prophylactic myocardial revascularization in patients with lung cancer allowed achieving comparable immediate and long-term results of surgical treatment of patients with lung cancer with concomitant coronary artery disease and without it.

1. Kim A. E., Charanjit S. R., Mary C. M., David R. H., Eric D. F., Bernard J. G. Cardiac risk of non-cardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation, 1997, Sep 16; № 96(6), рр. 1882–1887. https://doi.org/10.1161/01.cir.96.6.1882

2. Wong Y., Lawrence H., Wong D. The effects of prophylactic coronary revascularization or medical management on patient outcomes after non-cardiac surgery – a meta-analysis. Сanadian Journal of Anesthesia, 2007, № 54, рр. 705–717.

3. Raghunathan D., Palaskas N.L., Eagle K. Rise and fall of preoperative coronary revascularization. Expert Rev Cardiovasc Ther., 2020, May; № 18(5), рр. 249–259. https://doi.org/10.1080/14779072.2020.1757432

4. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Byrne R.A., Collet J.P., Falk V., Head S.J., Juni P., Kastrati A., Koller A., Kristensen S.D., Niebauer J., Richter D.J., Seferovic P.M., Sibbing D., Stefanini G.G., Windecker S., Yadav R., Zembala M.O. ESC/ EACTS Guidelines on Myocardial Revascularization ESC Clinical Practice Guidelines. Eur Heart J, 2019, Jan 7; № 40(2), рр. 87–165. https://doi.org/10.1093/eurheartj/ehy394

5. Kristensen S.D., Knuuti J., Saraste A., Anker S., Botker H.E., Hert S.D., Ford I., Gonzalez-Juanatey J.R., Gorenek B., Heyndrickx G.R., Hoeft A., Huber K., Iung B., Kjeldsen K.P., Longrois D., Luscher T.F., Pierard L., Pocock S., Price S., Roffi M., Sirnes P.A., Sousa-Uva M., Voudris V., Funck-Brentano C. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on noncardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J., 2014, Sep 14; № 35(35), рр. 2383–2431. https://doi.org/10.1093/eurheartj/ehu282

6. Halvorsen S., Mehilli J., Cassese S., Hall T.S., Abdelhamid M., Barbato E., Hert S.D., Laval I.D., Geisler T., Hinterbuchner L. , Ibanez B., Lenarczyk R., Mansmann U.R., McGreavy P., Mueller C., Muneretto C., Niessner A., Potpara T.S., Ristic A., Sade L.E., Schirmer H., Schupke S., Sillesen H., Skulstad H., Torracca L., Tutarel O., Meer P.V.D., Wojakowski W., Zacharowski K. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J., 2022, Oct 14; № 43(39), рр. 3826–3924. https://doi.org/10.1093/eurheartj/ehac270

7. Lawton J.S., Tamis-Holland J.E., Bangalore S., Bates E.R., Beckie T.M., Bischoff J.M., Bittl J.A., Cohen M.J., J Maio J.M., Don C.W., Fremes S.E., Gaudino M.F., Goldberger Z.D., Grant M.C., Jaswal J.B., Kurlansky P.A., Mehran R., Metkus Jr T.S., Nnacheta L.C., Rao S.V., Sellke F.W., Sharma G., Yong C.M., Zwischenberger B.A. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, Jan 18; № 145(3), рр. e4–e17. https://doi.org/10.1161/CIR.0000000000001039. Epub 2021 Dec 9

8. Gerasimov S.S., Davydov M.I., Davydov M.M. Modern strategy of surgical treatment of oncological patients with severe concomitant cardiovascular diseases. Russian Journal of Oncology, 2018, № 23, рр. 3–6. (In Russ.)

9. Voets A.J., Joesoef K.S., Teeffelen M.E.V. Synchroneously occurring lung cancer (stages I-II) and coronary artery disease: concomitant versus staged surgical approach. Eur. J. Cardiothorac. Surg., 1997, vol. 12, № 5, рр. 713–717.

10. Schoenmakers M.C., van Boven W.J., van den Bosch J., van Swieten H.A. Comparison of On-Pump or Off-Pump Coronary Artery Revascularization with Lung Resection. Ann. Thorac. Surg., 2007, vol. 84, № 2, рр. 504–509.

11. Porkhanov V.A., Barbukhatti K.O., Kononenko B.V., Belash S.Yu., Kovalenko A.L., Skopets A.A., Sitnik S.D., Polyakov I.S. Simultaneous operations on the heart and lung in coronary heart disease and malignant lung pathology in conditions of artificial circulation. Wedge and experiment. hir. Journal named after Academician B.V. Petrovsky, 2013, № 1, pp. 17–22. (In Russ.)

12. Tourmousogloua C.E., Apostolakisb E., Dougenisa D. Simultaneous occurrence of coronary artery disease and lung cancer: what is the best surgical treatment strategy? Interactive CardioVascular and Thoracic Surgery, 2014, № 19, рр. 673–681. https://doi.org/10.1093/icvts/ivu218

13. Kanzaki R., Kimura T., Kawamura T., Funaki S., Shintani Y., Minami M., Miyagawa Sh., Toda K., Sawa Y., Okumura M. Treatment of simultaneously discovered lung cancer and cardiovascular disease: a 20-year single-institution experience. Surgery Today, 2017, vol. 47, pр. 726–732.

14. Wang Z., Guo F., Li J., Sun D. Safety and efficacy of lobectomy combined with off-pump coronary artery bypass grafting for lung cancer. J Thorac Dis., 2021, Jul; № 13(7), рр. 4438–4447. https://doi.org/10.21037/jtd-21-788

15. Li Z., Liu B., Ge W., Zhang W., Gu Ch., Liu J., Ke X., Zhang Y. Effect of simultaneous surgical treatment of severe coronary artery disease and lung cancer. J Int Med Res, 2019, Feb; № 47(2), рр. 591–599.

16. Ciriaco P., Carretta A., Calori G., Mazzone P., Zannini P. Lung resection for cancer in patients with coronary arterial disease: analysis of short-term results. Eur J Cardiothorac Surg, 2002, № 22, рр. 35–40.

17. Al-Kindi S.G., Oliveira G.H. Prevalence of Preexisting Cardiovascular Disease in Patients with Different Types of Cancer: The Unmet Need for Onco-Cardiology. Mayo Clin Proc., 2016, Jan; № 91(1), рр. 81–83. https://doi.org/10.1016/j.mayocp.2015.09.009